Get all the latest news and updates on Insulin Aspart only on News18.com. Read Politics news, current affairs and news headlines online on Insulin Aspart News today.

Net loss of Natural Biocon (India) reported to Rs 0.01 crore in the quarter ended June 2026 as against net profit of Rs 0.14 crore during the previous quarter ...

Biocon Executive Chairperson Kiran Mazumdar-Shaw believes artificial intelligence should be viewed as a tool to push human ...

Biocon's Net Profit Margin significantly decreased from 9.36 percent in March 2025 to 2.17 percent in March 2026, a decline of 76.81 percent. The P/E ratio has risen sharply to 127.98x in March 2026 ...

In GEN’s flagship virtual event, The State of Biotech, we hear from a distinguished group of business executives, award-winning scientists, and journalists.

Biocon founder Kiran Mazumdar-Shaw has flagged the poor condition of Bengaluru’s Bommasandra-Jigani Link Road, highlighting ...

On July 29, 2026, Genentech, Inc. (“Genentech”) and Hoffmann-La Roche Inc. filed a complaint in the U.S. District Court for the District of New ...

Biocon expects to deliver a stronger performance as FY27 progresses, with growth momentum set to accelerate during the year ...

Indian biopharmaceutical company Biocon reported a more than fourfold jump in first-quarter net ​profit on Wednesday on strong revenue growth ‌from its biosimilars segment.

Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, today announced the commercial launch of Yesafili™ (aflibercept-jbvf) in the United States. YESAFILI, a ...

Yesafili, an interchangeable biosimilar to Eylea 2 mg, is now commercially available in the United States, according to a ...

Yesafili enters a growing U.S. aflibercept biosimilar class as the second launch after Amgen’s Pavblu, intensifying competition in high-volume retinal anti-VEGF indications. Interchangeable ...